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PURPOSE. Osteoprotegerin (OPG) is a novel regulator of endothelial cell function,
angiogenesis, and vasculogenesis. We correlated expression levels of OPG with those of
the angiogenic and inflammatory factors vascular endothelial growth factor (VEGF) and
monocyte chemoattractant protein-1 (MCP-1/CCL2) in proliferative diabetic retinopathy
(PDR). We also examined expression of OPG in retinas from diabetic rats and diabetic patients
and measured production of OPG by human retinal microvascular endothelial cells (HRMEC)
and investigated its angiogenic activity.
METHODS. Vitreous samples from 47 PDR and 28 nondiabetic patients, epiretinal membranes
from 14 patients with PDR, human retinas (10 from diabetic patients and 10 from nondiabetic
subjects), and rat retinas and HRMEC were studied by using enzyme-linked immunosorbent
assay, immunohistochemistry, immunofluorescence, Western blot analysis, and RT-PCR. In
vitro and in vivo angiogenesis assays were performed.
RESULTS. We showed a significant increase in the expression of OPG, VEGF, and MCP-1/CCL2
in a comparison between vitreous samples from PDR patients and those from nondiabetic
controls. Significant positive correlations were found between levels of OPG and levels of
VEGF and MCP-1/CCL2. In epiretinal membranes, OPG was expressed in vascular endothelial
cells and stromal cells. Significant increases of OPG mRNA and protein were detected in the
retinas from diabetic patients. The proinflammatory cytokines TNF-a and IL-1b, but not VEGF,
MCP-1/CCL2 or thrombin, induced upregulation of OPG in HRMEC. Osteoprotegerin induced
ERK1/2 and Akt phosphorylation in HRMEC and stimulated their migration. Osteoprotegerin
potentiated the angiogenic effect of VEGF in the in vivo protein gelatin plug assay.
CONCLUSIONS. These results suggest that OPG is involved in PDR angiogenesis.
Keywords: angiogenesis, monocyte chemoattractant protein-1, osteoprotegerin, proliferative
diabetic retinopathy, vascular endothelial growth factor
Ischemia-induced retinal angiogenesis and vasculogenesis arehallmark features of proliferative diabetic retinopathy (PDR)
and are critical steps for the development and progression of
PDR.1–4 Pathologic growth of new blood vessels and expansion
of extracellular matrix in association with the outgrowth of
fibrovascular epiretinal membranes at the vitreoretinal interface
often leads to catastrophic loss of vision due to vitreous
hemorrhage and/or traction retinal detachment. The dynamic
balance between proangiogenic and antiangiogenic factors is
thought to regulate angiogenesis.5 Vascular endothelial growth
factor (VEGF) is the major angiogenic factor in PDR that
promotes neovascularization and vascular leakage.6 In several
studies, the overexpression of proinflammatory and proangio-
genic molecules was demonstrated in the ocular microenviron-
ment of patients with PDR,7–12 suggesting that persistent
inflammation and neovascularization are critical for PDR
initiation and progression.
Our understanding of the precise molecular mechanisms
responsible for the regulation of retinal angiogenesis and
vasculogenesis in patients with PDR is incomplete and
molecular regulation of these processes is the subject of many
studies. A potential novel regulator of endothelial cell function,
angiogenesis, and vasculogenesis is osteoprotegerin (OPG), a
member of the TNF receptor superfamily. Osteoprotegerin
lacks a transmembrane domain and, unlike most members of
this family, is secreted into the extracellular space.13,14
Osteoprotegerin was initially identified for its role in regulating
bone metabolism by mediating paracrine signaling between
osteoblasts and osteoclasts.13–16 In addition to its role in bone
metabolism, OPG has recently been found to have additional
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roles in regulating endothelial cell function in tumor
angiogenesis and vascular disease.13,14 In addition, OPG may
be involved in development of vascular endothelial cell
dysfunction and micro- and macrovascular complications in
diabetes.17,18 The expression of OPG in PDR has not been
reported so far. Given the key roles of OPG in regulating
endothelial cell function and promotion of angiogenesis, we
investigated the hypothesis that OPG may be involved in PDR
pathogenesis.
MATERIALS AND METHODS
Vitreous Fluid Samples and Epiretinal Membranes
Specimens
Undiluted vitreous fluid samples were obtained from 47 PDR
patients during pars plana vitrectomy as described previous-
ly.7–12 The indications for vitrectomy were tractional retinal
detachment and/or nonclearing vitreous hemorrhage. The
control group consisted of 28 patients who had undergone
vitrectomy for the treatment of rhegmatogenous retinal
detachment with no proliferative vitreoretinopathy (PVR).
Controls were free from systemic disease. Epiretinal fibrovas-
cular membranes were obtained from 14 PDR patients during
pars plana vitrectomy for the repair of tractional retinal
detachment. Control epiretinal membranes were obtained
from 10 nondiabetic patients undergoing vitreoretinal surgery
for retinal detachment complicated by PVR. Membranes were
fixed for 2 hours in 10% formalin solution and embedded in
paraffin.
The study was conducted according to the tenets of the
Declaration of Helsinki. All patients were candidates for
vitrectomy as a surgical procedure. All patients signed a
preoperative informed written consent and approved the use
of the excised epiretinal membranes and vitreous fluid for
clinical research. The study design and protocol were
approved by the Research Centre and Institutional Review
Board of the College of Medicine, King Saud University.
Human Postmortem Eyes
Human postmortem eyes were obtained from 10 diabetic
individuals with mild nonproliferative diabetic retinopathy and
10 nondiabetic (control group) donors matched by age. After
enucleation, one eye from each donor was snap-frozen in
liquid nitrogen at808C and stored until assayed for mRNA or
protein analyses. Neuroretina and retinal pigment epithelium
(RPE) were quickly harvested. Vitreous and neuroretinas were
removed, and the RPE layer was carefully peeled from Bruch’s
membrane, using forceps (Dumont no. 5; Sigma, Madrid,
Spain) under a dissecting microscope (model SZ61; Olympus,
Barcelona, Spain). The other eye was fixed in 4% paraformal-
dehyde and embedded in paraffin.
All ocular tissues were used in accordance with applicable
laws and with tenets of the Declaration of Helsinki for research
involving human tissue. In addition, this study was approved
by the Ethics Committee, Institut de Recerca Hospital
Universitari Vall d’Hebron.
Rat Streptozotocin-Induced Diabetes Model
All procedures with animals were performed in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research and were approved by the Institutional
Animal Care and Use Committee of the College of Pharmacy,
King Saud University. Diabetes was induced in adult male
Sprague-Dawley rats, by intraperitoneal injection of strepto-
FIGURE 1. Comparisons of mean OPG, VEGF, and MCP-1/CCL2 ELISA
levels in vitreous fluid samples from patients with PDR (n ¼ 47) and
those from nondiabetic patients with rhegmatogenous RD (n ¼ 28).
The difference between the two means was statistically significant at
5% level of significance.
Osteoprotegerin in PDR IOVS j June 2017 j Vol. 58 j No. 7 j 3190
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936282/ on 07/04/2017
zotocin (Sigma) as described previously.7 After 4 and 12 weeks
of diabetes, animals were sacrificed, and retinas were
dissected, flash frozen, and stored at 708C. Similarly, retinas
were obtained from age-matched nondiabetic control rats.
Enzyme-Linked Immunosorbent Assays for
Vitreous Samples
Enzyme-linked immunosorbent assay (ELISA) kits for human
osteoprotegerin (catalog no. DY-805), MCP-1/CCL2 (catalog no.
DCP00), and VEGF (catalog no. SVE00) were purchased from
R&D Systems, Minneapolis, MN, USA.
Western Blot Analysis for OPG Expression in
Human Vitreous Fluid Samples and Rat Retinas
Retinas from diabetic and control rats were homogenized in
Western blot lysis buffer as described previously,7 and
homogenates were subjected to sodium dodecyl sulfate
(SDS)-PAGE. Equal volumes (15 lL) of vitreous samples were
boiled (10 min) in Laemmli’s sample buffer (1:1 v/v) under
reducing conditions and analyzed as described previous-
ly.7,11,12 Blots were incubated overnight with anti-OPG
antibody (1:1000 silution; clone ab73400; Abcam, Cambridge,
UK) at 48C.
Immunohistochemical Staining of Epiretinal
Membranes
For CD31, a-smooth muscle actin (a-SMA), and OPG detection,
antigen retrieval (10-minute incubation) was performed using
citrate based buffer (pH 5.9 to 6.1; Bond epitope retrieval
solution 1; Leica Biosystems, Buffalo Grove, IL, USA). For CD45
detection, antigen retrieval (20-minute incubation) was per-
formed using Tris/EDTA buffer (pH 9) (Bond epitope retrieval
solution 2; Leica). Subsequently, the sections were incubated
(60 minutes) with mouse monoclonal anti-CD31 antibody
(clone JC70A; Dako, Glostrup, Denmark), mouse monoclonal
anti-CD45 antibody (clones 2B11 and PD7/26; Dako), mouse
monoclonal anti-a-SMA antibody (clone 1A4; Dako), and rabbit
polyclonal anti-OPG antibody (1:50 dilution; clone ab9986;
Abcam) as described.3,7,11,12 To identify the phenotype of cells
expressing OPG, sequential double immunohistochemistry
was performed as described.3,7,11,12
Immunoreactive blood vessels and cells were counted in
five representative fields using an eyepiece calibrated grid in
combination with the 403 objective. With this magnification
and calibration, immunoreactive blood vessels and cells
present in an area of 0.333 0.22 mm were counted.
Immunofluorescent Detection of OPG in Retinas
From Diabetic Patients
Retinal sections (7-lm thickness) were pretreated as de-
scribed,19 blocked (2% bovine serum albumin in 0.05% Tween
in phosphate-buffered saline for 1 hour), and incubated
overnight with primary antibody against OPG (1:500 dilution;
clone ab73400; Abcam). Colocalization studies were per-
formed using anti-glial fibrillary acidic protein (GFAP) (1:1000
dilution; clone ab10062; Abcam), anti-Iba1 (1:200 dilution;
clone ab5076; Abcam), and anti-collagen IV (1:50 dilution;
clone ab6311; Abcam). After sections were washed, they were
incubated with Alexa Fluor 488 or 594 secondary antibodies
(Molecular Probes, Invitrogen, Madid, Spain) at room temper-
ature for 1 hour. Slides were cover-slipped with mounting
medium containing 40,6-diamidino-2-phenylindole (DAPI) for
visualization of cell nuclei (Vector Laboratories, Palex, Sant
Cugat del Valle´s, Spain). Images were acquired with a confocal
laser scanning microscope (model FV1000; Olympus).
Analysis of OPG Expression in Retinas From
Diabetic Patients
Human neuroretina and RPE were harvested under the
microscope. For Western blot analysis, neuroretina and RPE
samples were extracted with radioimmunoprecipitation assay
buffer and homogenized by sonication. The protein concen-
tration was determined using a bicinchoninic acid protein
assay (Bio-Rad Laboratories, Madrid, Spain). Protein extracts
(20 lg) were resolved by 10% SDS-PAGE and transferred to ECL
nitrocellulose membranes (Hybond; Amersham Pharmacia
Biotech, Little Chalfont, UK). Membranes were first incubated
with anti-OPG (1:1000 dilution; clone ab73400; Abcam) and
afterward with peroxidase-conjugated secondary antibody
(Bio-Rad Laboratories). Proteins were visualized using the
enhanced chemiluminescence detection system (Supersignal
CL-horseradish peroxidase substrate system; Thermo Scientific,
Rockford, lL, USA).
FIGURE 2. Determination of OPG levels in vitreous fluid. Equal volumes (15 lL) of vitreous fluid samples from patients with PDR (n¼16) and from
nondiabetic patients with rhegmatogenous RD (n¼ 8) were analyzed using PAGE, and the presence of OPG was detected by using Western blot
analysis. A representative set of samples (three RD samples and three PDR samples) is shown (left panel). The intensity of the protein band around
50 kDa was determined in all samples (right panel). *P < 0.05 (Mann-Whitney U test).
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Total RNA was extracted from isolated retinal tissues by
using Trizol reagent (Invitrogen). Concentrations of RNA were
determined, and reverse transcription was performed using 1
lg of total RNA, using random hexanucleotide priming and
reagents provided by Applied Biosystems, Madrid, Spain.
The power SYBR Green PCR Master Mix (Applied
Biosystems) was used for real-time PCR, and reactions were
conducted at 958C for 10 min, for 50 cycles of 15 seconds each
at 958C, and for 1 minute at 608C, using the Prism 7000 unit
(Applied Biosystems). Each sample was assayed in duplicate,
and control negative samples were included in each experi-
ment. Specific primer pairs corresponding to human OPG
(forward primer 5 0-TGGCACCAAAGTAAACGCAGAG-30 and
reverse primer 50-CTCGAAGGTGAGGTTAGCATGTC-30) and
human b-actin (as endogenous control: forward primer 50-
TGGAGAAAATCTGGCACCAC-3 0 and reverse primer 5 0-
GAGGCGTACAGGGATAGCAC-30) were used.
Induction of Human Retinal Microvascular
Endothelial Cells
Human retinal microvascular endothelial cells (HRMEC; Cell
Systems, Kirkland, WA, USA) were cultured as described.10
Confluent monolayers were stimulated with VEGF (Biolegend,
San Diego, CA, USA), IL-1b (Peprotech, Rocky Hill, NJ, USA),
TNF-a (Peprotech), MCP-1/CCL2 (Peprotech) and thrombin
(Sigma). In addition, 25 mM of mannose (osmotic control) or 25
mM of glucose was added to the stimulation medium to evaluate
FIGURE 3. Osteoprotegerin is expressed in epiretinal membranes from patients with PDR. Expression of OPG in PDR epiretinal membranes was
investigated by immunohistochemistry analysis using a specific anti-OPG antibody. Specificity was checked by use of an irrelevant polyclonal
antibody (A) (negative control). Microvessels, infiltrating leukocytes, and myofibroblasts were stained using anti-CD31 (B), anti-CD45 (C), and anti-a-
smooth muscle actin (D) antibodies, respectively. Immunoreactivity for OPG was observed in the vascular endothelium (arrows) (E) and in stromal
spindle-shaped cells (arrowheads) (F). Double-immunohistochemistry analysis was performed using CD45 (brown) and OPG (red), and co-staining
was detected in stromal cells (arrows) (G) (original magnification340).
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the effect of hyperglycemia. All inductions were performed in
duplicate. After 72 hours, cell supernatants were harvested,
centrifuged to remove cell debris and stored at208C.
Signal Transduction Assays for Phosphorylated
Akt and Extracellular Signal-Regulated Kinase
(ERK)1/2
Signal transduction experiments with HRMEC were performed
as described previously.10
Chemotaxis Assay
The chemotactic activity of recombinant human OPG
(TNFRSF11B; R&D Systems) for HRMEC was evaluated using
cell invasion/migration plates and the RTCA-DPx CELLigence
instrument (Acea Biosciences, San Diego, CA, USA). This system
records changes of electrical impedance, which is expressed as
cell index (CI) over a prolonged time course. First, 160 lL of
stimulus (control medium, OPG, or VEGF) and 50 lL of EBM-2
with 0.4% fetal bovine serum (FBS; control medium) was added
to the lower and upper chambers, respectively. Subsequently,
the CIM16-plate was equilibrated (1 hour, 378C). Afterward,
HRMECs (40,000 cells per well; 100 lL/well) were seeded in the
upper chamber in EBM-2 medium containing 0.4% FBS and
allowed to settle onto the membrane (30 minutes, 208C). After
transfer to a CO2 incubator (378C), the impedance value was
monitored every minute during 15 hours and expressed as CI.
Cells migrating across the membrane cause an increase in the
CI. Each experiment was performed in duplicate.
In Vivo Gelatin Protein Plug Assay
Cooled growth factor-reduced protein gelatin (9 to 11 mg of
protein/mL; Matrigel; BD Biosciences, San Jose, CA, USA) was
injected subcutaneously (500 lL/mouse) into the flank of 7-8
week-old female C57/Bl6 mice. The first group of mice were
injected pure protein gelatin as control, others received
protein gelatin mixed with either VEGF (250 ng), OPG (500
ng), or VEGF (250 ng) plus OPG (500 ng). After 7 or 8 days,
plugs were resected and digested for 1hour at 378C with
dispase (15 U/mL) in the presence of DNase (10,000 U/mL) to
obtain single-cell suspensions. The total number of cells
recovered from each plug was determined, and the cell
suspensions were incubated with antibodies against CD45
and CD34 (clones 30-F11 and RAM34; eBioScience, San Diego,
CA, USA), to distinguish between leukocytes and endothelial
cells, respectively. Using flow cytometry the number of
endothelial cells recruited into the plugs was determined.
Statistical Analysis
Data are mean 6 SD or SEM. The nonparametric Mann-Whitney
U test was used to compare means from two independent
groups. Pearson correlation coefficients were computed to
investigate correlation between variables. A P value less than
0.05 indicated statistical significance. SPSS version 20.0
software (IBM, Armonk, NY, USA) for Windows (Microsoft,
Redmond, WA, USA) was used for statistical analysis.
RESULTS
ELISA Levels of OPG, VEGF, and MCP-1/CCL2 in
Vitreous Samples From PDR Patients
OPG was detected in 24 of 28 vitreous samples (86%) from
nondiabetic control patients, as well as in 45 of 47 PDR samples
(96%). Mean OPG level in PDR patients (364.5 6 163.3 pg/mL)
was significantly higher than mean level in nondiabetic control
patients (150.4 6 121.1 pg/mL) (P < 0.0001). VEGF was
detected in 17 of 28 samples (60.7%) from controls, and in 38 of
47 PDR samples (80.9%). Mean VEGF level in PDR patients
(1026 6 1442.7 pg/mL) was significantly higher than mean
level in controls (38.36 81.1 pg/mL; P < 0.0001). MCP-1/CCL2
was detected in 25 of 28 samples (89%) from controls and in 45
of 47 samples (96%) samples from PDR patients. Mean MCP-1/
CCL2 level in PDR patients (999.2 6 354 pg/mL) was
FIGURE 4. Immunostaining of proliferative vitreoretinopathy fibrocellular epiretinal membranes. Immunohistochemical staining for CD31 showing
no immunoreactivity (A). Immunohistochemical staining for a-smooth muscle actin shows immunoreactivity in spindle-shaped myofibroblasts (B).
Immunohistochemical staining for CD45 shows immunoreactivity in leukocytes (C). Immunohistochemical staining for osteoprotegerin shows no
immunoreactivity (D) (original magnification340).
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FIGURE 5. (A) Osteoprotegerin mRNA is more abundant in retinas from subjects with diabetes. Expression of OPG mRNA was analyzed by using
real-time quantitative RT-PCR in retinal RPE and neuroretina (NR). Osteoprotegerin mRNA expression was calculated after normalization of b-actin
mRNA levels. Bars represent mean6 SD of the relative quantification (RQ) values obtained for mRNA levels in diabetic (D) (n¼10) and nondiabetic
(C) (n¼10) donors. *P < 0.05 (Mann-Whitney U test). (B) Osteoprotegerin protein expression is upregulated in retinas from subjects with diabetes.
Osteoprotegerin protein expression was determined by Western blot analysis on lysates of RPE and NR from representative diabetic (D) (n¼ 3) and
nondiabetic (C) (n¼3) donors. Intensities of the protein bands around 50 kDa were determined in all samples (n¼10/group). Data (arbitrary units)
are mean 6 SD. *P < 0.05 (Mann-Whitney U test).
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significantly higher than mean level in nondiabetic control
patients (543 6 271.9 pg/mL; P < 0.0001) (Fig. 1).
Significant positive correlations were found between vitre-
ous fluid levels of OPG and levels of VEGF (r¼ 0.33; P¼ 0.006)
and MCP-1/CCL2 (r¼ 0.41; P¼ 0.001). In contrast, the vitreous
fluid levels of VEGF and MCP-1/CCL2 did not correlate.
Western Blot Analysis of Vitreous Samples
Using Western blot analysis, we confirmed that OPG was
present in vitreous samples and that OPG expression was
enhanced in PDR. Osteoprotegerin migrated at the position of
its expected molecular weight and indeed, densitometric
FIGURE 6. (A) Microscopy analysis of OPG expression in human retina. Immunofluorescent staining of OPG in representative samples from
nondiabetic (C) and diabetic (D) donors. After fixation, retinas were stained with a polyclonal rabbit anti-OPG antibody (green) and anti-glial
fibrillary acidic protein antibody (red) to show glial activation. Nuclei were labeled with DAPI (blue). INL, inner nuclear layer; ONL, outer nuclear
layer; RGL, retinal ganglion layer. (B) Osteoprotegerin colocalized with GFAP, Iba1, and collagen IV in human diabetic retina. (a) Osteoprotegerin
immunofluorescence (green). (b) GFAP immunofluorescence (red). (c) Osteoprotegerin (green); GFAP (red), and nuclei (DAPI stain) (blue).
Orange fluorescence (white arrows) shows colocalization of both fluorescent colors. (d) Osteoprotegerin immunofluorescence (green). (e) Iba1
immunofluorescence (red). (f) Osteoprotegerin (green), Iba1 (red), and nuclei (blue). Orange fluorescence (white arrows) shows colocalization of
both fluorescent colors. (g) Osteoprotegerin (green). (h) collagen IV (red). (i) Osteoprotegerin (green), collagen IV (red), and nuclei (blue). Orange
fluorescence (white arrows) shows colocalization in retinal vessels. INL, inner nuclear layer; ONL, outer nuclear layer; RGL, retinal ganglion layer.
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analysis of the 50 kDa band demonstrated a significant increase
in OPG expression in samples from PDR patients (n ¼ 16)
compared to samples from nondiabetic control patients (n¼ 8;
P ¼ 0.02) (Fig. 2).
Immunohistochemical Analysis of Fibrovascular
Epiretinal Membranes From Patients With PDR
To identify the cellular source of vitreous fluid OPG,
fibrovascular epiretinal membranes from patients with PDR
were studied using immunohistochemical analysis. No staining
was observed in the negative control slides (Fig. 3A). The levels
of vascularization and proliferative activity in epiretinal
membranes from patients with PDR were determined by
immunodetection of the endothelial cell marker CD31. All
membranes showed blood vessels that were positive for CD31
(Fig. 3B) with a mean of 33.7 6 23.2 (range, 8 to 95) vessels
per specimen. Leukocytes expressing the leukocyte common
antigen CD45 (Fig. 3C) and spindle-shaped cells expressing the
myofibroblast marker a-SMA (Fig. 3D) were detected in all
membranes. Immunoreactivity for OPG was present in all
membranes and was noted in vascular endothelial cells and
stromal cells (Fig. 3E, 3F). Most of the OPG-positive stromal
cells were spindle shaped (Fig. 3F). In serial sections, the
distribution and morphology of spindle-shaped cells express-
ing OPG were similar to those of cells expressing a-SMA (Fig.
3D). Double immunohistochemistry showed that few stromal
cells expressing OPG coexpressed CD45 (Fig. 3G). In
comparison, there was no immunoreactivity for CD31 (Fig.
4A) and OPG (Fig. 4D) in epiretinal membranes from patients
with PVR. On the other hand, all PVR membranes showed
myofibroblasts expressing a-SMA (Fig. 4B) and leukocytes
expressing CD45 (Fig. 4C).
The number of blood vessels that were immunoreactive for
OPG ranged from 4 to 60, with a mean of 15.9 6 17.3 per
specimen. The number of OPG-positive stromal cells ranged
from 3 to 105 cells, with a mean of 34.4 6 36.9 per specimen.
Significant positive correlations were detected between the
numbers of blood vessels expressing CD31 and the numbers of
blood vessels (r¼0.89; P < 0.0001) and stromal cells (r¼0.56;
P ¼ 0.036) expressing OPG.
Effect of Diabetes on Retinal OPG Expression in
Humans and Rats
OPG mRNA expression was higher in diabetic donors than in
nondiabetic donors in both RPE and neuroretina (P < 0.001 for
both comparisons) (Fig. 5A). Western blot analysis demonstrat-
ed that OPG protein expression was upregulated in diabetic
retinas compared to nondiabetic control retinas in RPE as well
as in neuroretina (P < 0.001 for both comparisons) (Fig. 5B).
Immunostaining for OPG was observed in the cytoplasm of all
FIGURE 7. Osteoprotegerin protein expression in the retinas of diabetic rats. Osteoprotegerin protein expression was determined by Western blot
analysis on lysates of diabetic (D) and nondiabetic control (C) rats. After determination of the intensity of the protein band around 50 kDa,
intensities were adjusted to those of b-actin in the sample. Each measurement was performed at least three times. Results are mean 6 SD data from
at least 6 rats in each group.
FIGURE 8. Osteoprotegerin is produced by HRMEC. HRMEC were
incubated for 72 hours with thrombin (1 to 25 U/mL), MCP-1 (30 or
300 ng/mL), VEGF (2 to 50 ng/mL), IL-1b (2 to 50 ng/mL), TNF-a (2 to
50 ng/mL), combinations of IL-1b plus TNF-a (10 and 10 ng/mL or 50
and 50 ng/mL), MCP-1/CCL2 plus VEGF (30 and 30 ng/mL), VEGF plus
thrombin (10 ng/mL and 5 U/mL or 10 ng/mL and 25 U/mL) or were
left untreated (C) as described in Materials and Methods. Results are
mean (6 SEM). Osteoprotegerin concentrations were measured by
ELISA (n¼ 4). *P < 0.05.
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retinal layers (Fig. 6A). In addition, double immunofluores-
cence analysis revealed that OPG was colocalized with the glial
cell marker GFAP, the microglial cell marker Iba1 and the basal
lamina marker collagen IV (Fig. 6B).
We quantified the expression of OPG in rat retinas by
Western blot analysis. Densitometric analysis of the bands
revealed that the expression of OPG did not differ significantly
between nondiabetic controls and diabetic rat retinas after 4
and 12 weeks of acutely induced diabetes (Fig. 7).
Human Retinal Microvascular Endothelial Cells
Produce OPG In Vitro
To confirm our findings that vascular endothelial cells in PDR
fibrovascular epiretinal membranes express OPG, we investi-
gated whether HRMEC could produce OPG. To reach that goal,
we treated HRMEC for 72 hours with cytokines or growth
factors known to be present in the ocular microenvironment of
patients with PDR, in particular MCP-1/CCL2, VEGF, thrombin,
IL-1b, and TNF-a. Unstimulated HRMEC did release a significant
amount of OPG (about 45 pg/mL) in the culture medium (Fig.
8). The production of OPG by HRMEC was not upregulated in
response to MCP-1/CCL2, VEGF or thrombin added as single
stimulus or in combination. However, the cytokines IL-1b and
TNF-a alone or in combination did increase the levels of OPG
in the culture medium. In response to IL-1b plus TNF-a up to
15 ng/mL of OPG was detected by specific ELISA. Raising the
glucose concentration of the culture medium to 25 mM did not
affect spontaneous and stimulated release of OPG (data not
shown).
OPG Induces Human Retinal Microvascular
Endothelial Cell Migration
In order to investigate whether OPG affected HRMEC
migration, real-time impedance-based recording of migration
was performed using the xCELLigence system. HRMEC were
stimulated with different doses of OPG, and migration was
followed over 15 hours. Figure 9A shows the recorded cell
indexes from one representative experiment. In total 4
experiments were performed and statistically evaluated. When
results were expressed relative to the cell index of spontane-
ously migrating HRMEC, OPG significantly stimulated endo-
thelial cell migration at 20 and 100 ng/mL (154 6 17% and 153
6 14%, respectively) (Fig. 9B). For comparison, VEGF, a potent
inducer of endothelial cell migration, was also used as
chemoattractant. VEGF at 5 ng/mL significantly increased
endothelial cell migration to 337 6 42% (data not shown).
OPG Activates Signal Transduction Pathways in
Human Retinal Microvascular Endothelial Cells
Next, we verified whether OPG was able to activate ERK1/2
and Akt signal transduction pathways. Similar to the angiogenic
factor VEGF (30 ng/mL), OPG induced significant phosphor-
ylation of these two kinases (Fig. 10). The minimal effective
concentration of OPG, 300 ng/mL was, however, at least 10-
FIGURE 9. Osteoprotegerin stimulates retinal endothelial cell migration. HRMEC were treated with recombinant human OPG at the indicated
concentrations. Migration was monitored for 15 hours, using the xCELLigence system. (A) Representative experiment. (B) Cell indexes recorded
after 15 hours of incubation were divided by the average index from cells migrating toward dilution buffer (C). Results (mean percentage 6 SEM)
are derived from 3 or 4 independent experiments. *P < 0.05.
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fold higher than that of VEGF and OPG was not as efficacious
as VEGF.
OPG Induces In Vivo Angiogenesis
Finally, we evaluated the angiogenic activity of OPG in protein
gelatin plugs implanted subcutaneously in mice. In addition to
control plugs (no extra stimulus; n¼ 12), plugs containing 500
ng/mL OPG (n ¼ 9), 250 ng/mL VEGF (n ¼ 10), or OPG plus
VEGF (n ¼ 12) were created. VEGF and the combination of
VEGF plus OPG significantly increased the total number of
cells recruited to the plugs (Fig. 11). Flow cytometric analysis
demonstrated that an important part of the cells present in the
plugs expressed CD34 in the absence of CD45, confirming that
blood vessels (lined with endothelial cells) developed in the
plugs, as could be observed macroscopically. In addition, OPG
was able to enhance the effect of VEGF, suggesting that in eyes
of diabetic patients where both OPG and VEGF are present,
those endothelial growth factors cooperate in the induction of
pathological neovascularization.
DISCUSSION
In the present study, we showed that OPG was significantly
upregulated in the vitreous fluid from patients with PDR and in
the retinas from subjects with diabetes mellitus. As yet it is
unclear why the statistical differences observed in the levels of
OPG in patients were not observed in the animal model. One
possible explanation is the fact that the rat model represents
short-term effects of an acute diabetogenic event, whereas in
the patients, the disease evolved over much longer time
intervals, eventually years. Using immunohistochemistry, we
demonstrated that OPG protein was specifically produced by
vascular endothelial cells, myofibroblasts and leukocytes in
PDR fibrovascular epiretinal membranes. Our data are in line
with those of others who have shown that OPG is expressed by
endothelial cells, macrophages and fibroblasts in the microen-
vironment of tumors and inflammatory disorders.20–24
Although OPG was first described as a modulator of bone
metabolism, an increasing number of reports now consider
OPG also has a function in other biological systems, including
promotion of angiogenesis and vasculogenesis.13,20 The
angiogenic process requires activation and invasion of endo-
thelial cells through their basement membrane, proliferation,
migration and re-establishment of cell-cell contacts to form
patent tubes. It has been demonstrated that OPG contributes
to each of these events. Involvement of the heparin-binding
domain of OPG in the proangiogenic activity of OPG was
suggested.20,25–27 In addition, it was demonstrated that OPG
enhanced the proangiogenic effect of VEGF.26 Similarly, in the
present study, we demonstrate that OPG potentiated VEGF-
induced angiogenesis in protein gelatin plugs implanted
subcutaneously in mice. Additionally, OPG protects endothelial
cells from apoptosis induced by growth factor withdrawal.28
OPG’s endothelial survival function appears to derive from its
ability to inhibit TNF-related apoptosis inducing ligand (TRAIL)-
mediated apoptosis.29 Furthermore, OPG stimulates endothe-
lial colony-forming cell survival, migration, chemotaxis and
FIGURE 10. Osteoprotegerin activates the intracellular kinases Akt and ERK1/2 in HRMEC. HRMEC were stimulated with OPG (at concentrations of
300, 100, or 30 ng/mL) or with VEGF (30 ng/mL) for 15 minutes. The phospho-ERK1/2-to-total protein content ratio (upper panel) or phospho-Akt-
to-total protein content ratio (lower panel) was calculated for cell lysates of HRMEC after 15 minutes of incubation with the applied stimulus.
Results represent a percentage (mean 6 SEM) of the kinase phosphorylation status after buffer (C) treatment. n¼ 4; *P < 0.05.
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vascular cord formation suggesting that OPG is involved in
vasculogenesis.30,31
In the present study, we found a significant positive
correlation between the vitreous fluid levels of OPG and those
of the angiogenic and inflammatory biomarkers VEGF and
MCP-1/CCL2. Using immunohistochemistry, we demonstrated
a significant positive correlation between the level of
vascularization in PDR epiretinal membranes and the number
of blood vessels and stromal cells expressing OPG. Taken
together, these findings suggest that upregulation of OPG in
the ocular microenvironment of PDR patients might contribute
to the progression of angiogenesis associated with PDR. To
corroborate the findings at the cellular level, stimulation with
OPG induced HRMEC migration, a key early step in angiogen-
esis. In addition, we showed that OPG can activate proliferative
(ERK1/2) and survival (Akt) signaling pathways in HRMEC,
further underscoring its role as a promoter of PDR angiogen-
esis. Our data are consistent with previous reports that
demonstrated the ability of OPG to induce activation of the
angiogenic signaling pathways ERK1/2 and Akt in endothelial
cells.27,31,32
Chronic low-grade subclinical inflammation plays a central
role in the development of diabetic retinopathy.33 In this
respect, it should be emphasized that OPG release by
endothelial cells is significantly upregulated by the proinflam-
matory cytokines TNF-a, IL-1a, and IL-1b18,26,34 as also shown
in this study for HRMEC. These findings suggest that
inflammation might be involved in diabetes-induced retinal
endothelial structural damage by inducing OPG expression.
Elevated levels of OPG have been observed in chronic
inflammatory diseases,35–38 suggesting that OPG is a marker
of inflammation. Previous reports demonstrated that OPG has
proinflammatory properties by activation of classic nuclear
factor-kappa B (NF-jB) signaling.39 Furthermore, a pathologic
role of OPG was also supported by an in vitro study showing
that administration of OPG promoted the adhesion of
leukocytes to endothelial cells. There is evidence that the
heparin-binding domain of OPG is involved in mediating its
pro-adhesive activity.40 OPG also stimulates upregulation of the
endothelial adhesion molecules intercellular adhesion mole-
cule-1, vascular cell adhesion molecule-1 and E-selectin in TNF-
a-activated endothelial cells and facilitates binding of mono-
cytes.41 Because an abnormal increase of leukocyte/endothe-
lial cell adhesion is considered an early step in diabetes-
induced retinal vasculopathy,33 these data suggest that
pathological increase of OPG in the ocular microenvironment
of patients with PDR may contribute to the inflammatory status
of the endothelium in PDR.
In conclusion, our findings suggest that OPG may be
specifically involved in promoting the progression of patho-
logic neovascularization in the ocular microenvironment of
PDR patients. Therapeutic strategies aimed to decrease OPG
levels may be suitable for improving the vascular function in
diabetic retina.
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